Spin-Off Companies
UBC has a world-class reputation for its commercialization activities, and the Michael Smith Laboratories is proud to be part of this recognized success. One of the university's most successful spin-off companies, Neuromed Pharmaceuticals (now Zalicus) started in the research laboratory of Dr. Terry Snutch. In 2006 Neuromed Pharmaceuticals entered into an almost half-a-billion dollar agreement with Merck & Co. in what was the largest licensing deal in Canada's biotech history. Research in the Michael Smith Laboratories is helping to transform promising science into product-driven deals. | |
| 1992 | Biomarin Pharmaceuticals (note: formerly Synapse Technologies) |
| 1995 | Neuromed Technologies (acquired by Zalicus) |
| 1998 | Raven Biotech. Inc. |
| 2000 | TapImmune (formerly GeneMax Pharmaceuticals Inc.) |
| 2002 | Inimex Pharmaceuticals Inc. |
| 2008 | BiOasis |
| 2010 | Vedanta |
